Common Stock, par value $0.001 per share
- Symbol
- ANNX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.07 · 8-K
Annexon, Inc.
ANNXNASDAQEQUITYCurrent
Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. Annexon, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2026. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to eac…
Company context
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Current securities
Recent company filings
- 10-Q filingAug 12, 2026
- Results of Operations and Financial Condition · Other EventsAug 12, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 10, 2026
- Other EventsAug 6, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other EventsJul 30, 2026
Registered securities in this filing
ANNEXON, INC. · 8-K · Filed 2026-06-12
Disclosure sections
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07. Submission of Matters to a Vote of Security Holders.
Annexon, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2026. The following is a brief description of each matter voted upon at the Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.
The election of two nominees to serve as Class III directors for a three-year term to expire at the 2029 annual meeting of stockholders or until such earlier time as their respective successors are duly elected and qualified. The following two Class III directors were elected by the votes indicated.
For Withheld Broker Non-Votes
───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Bettina M. Cockroft, M.D. 101,594,745 22,807,949 17,818,815
Douglas Love, Esq. 107,491,451 16,911,243 17,818,815
The ratification of the selection by the Audit Committee of our Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The selection was ratified by the votes indicated.
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
For Against Abstain Broker Non-Votes
───────────────────────────────────────────────────────────────
142,016,122 185,546 19,841 —
The approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.
For Against Abstain Broker Non-Votes
─────────────────────────────────────────────────────────────────
122,347,513 1,986,387 68,794 17,818,815
The approval of an amendment to the Company’s amended and restated certificate of incorporation to increase the number of authorized shares of common stock from 300,000,000 to 500,000,000.
For Against Abstain Broker Non-Votes
───────────────────────────────────────────────────────────────────
129,051,256 4,374,799 8,795,454 —